What is the official website of AbbVie | Oncology ?

The official website of AbbVie | Oncology is https://www.abbvie.com/our-science/therapeutic-focus-areas/oncology.html.

What is AbbVie | Oncology's cybersecurity risk score?

AbbVie | Oncology has an AI-generated cybersecurity risk score of 758 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has AbbVie | Oncology experienced?

According to Rankiteo, AbbVie | Oncology currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has AbbVie | Oncology been affected by any supply chain cyber incidents ?

According to Rankiteo, AbbVie | Oncology has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does AbbVie | Oncology have SOC 2 Type 1 certification ?

According to Rankiteo, AbbVie | Oncology is not certified under SOC 2 Type 1.

Does AbbVie | Oncology have SOC 2 Type 2 certification ?

According to Rankiteo, AbbVie | Oncology does not hold a SOC 2 Type 2 certification.

Does AbbVie | Oncology comply with GDPR ?

According to Rankiteo, AbbVie | Oncology is not listed as GDPR compliant.

Does AbbVie | Oncology have PCI DSS certification ?

According to Rankiteo, AbbVie | Oncology does not currently maintain PCI DSS compliance.

Does AbbVie | Oncology comply with HIPAA ?

According to Rankiteo, AbbVie | Oncology is not compliant with HIPAA regulations.

Does AbbVie | Oncology have ISO 27001 certification ?

According to Rankiteo,AbbVie | Oncology is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does AbbVie | Oncology operate in ?

AbbVie | Oncology operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does AbbVie | Oncology have ?

AbbVie | Oncology employs approximately None employees people worldwide.

Does AbbVie | Oncology own any subsidiaries ?

AbbVie | Oncology presently has no subsidiaries across any sectors.

How many LinkedIn followers does AbbVie | Oncology have ?

AbbVie | Oncology's official LinkedIn profile has approximately 19,504 followers.

What is the NAICS classification code for AbbVie | Oncology ?

AbbVie | Oncology is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does AbbVie | Oncology have a Crunchbase profile ?

No, AbbVie | Oncology does not have a profile on Crunchbase.

Does AbbVie | Oncology have a LinkedIn profile ?

Yes, AbbVie | Oncology maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/abbvie-oncology.

How many cybersecurity incidents has AbbVie | Oncology experienced ?

As of August 11, 2026, Rankiteo reports that AbbVie | Oncology has experienced 2 cybersecurity incidents.

How many peer or competitor companies does AbbVie | Oncology have ?

AbbVie | Oncology has an estimated 5,728 peer or competitor companies worldwide.

What types of cybersecurity incidents has AbbVie | Oncology faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Vulnerability.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Boost Score +25 with badge (5 left)

758

/1000

Fair

783

/1000

Fair

AbbVie | Oncology Vendor Cyber Rating & Cyber Score

abbvie.com

Add Your Compliance Badge

Follow AbbVie's oncology page for global news and updates about our commitment to discover and develop therapies that aim to address the unmet needs of people affected by cancer. Review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html

AO A.I CyberSecurity Scoring

Scoring History

AbbVie | Oncology CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

AbbVie

Vulnerability

100

4/2026

EGAABB177565877...

AbbVie | Oncology

Breach

100

6/2023

ABB0473723

Loading…

A.I.

AO Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for AO

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for AbbVie | Oncology in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for AbbVie | Oncology in 2026.

Incident Types AO vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for AbbVie | Oncology in 2026.

Incident History - AO (X = Date, Y = Severity)

Loading…

SUBSIDIARY

AbbVie | Oncology Subsidiaries

AO

Pharmaceutical Manufacturing

Website: https://www.abbvie.com/our-science/therapeutic-focus-areas/oncology.html

Company Size: 10,001+ employees

AbbViePharmaceutical Manufacturing

AbbVieEyetoEyePharmaceutical Manufacturing

Allergan AestheticsPharmaceutical Manufacturing

CoolSculptingMedical Equipment Manufacturing

BOTOX® Cosmetic (onabotulinumtoxinA)Pharmaceutical Manufacturing

Allergan Medical InstitutePharmaceutical Manufacturing

Allergan Aesthetics Plastic and Regenerative Medicine PortfolioMedical Equipment Manufacturing

Natrelle Breast ImplantsPharmaceutical Manufacturing

JUVÉDERM® Collection of FillersPharmaceutical Manufacturing

Pharmacyclics, an AbbVie CompanyPharmaceutical Manufacturing

ImmunologyPharmaceutical Manufacturing

NeurosciencePharmaceutical Manufacturing

Allergan Eye CarePharmaceutical Manufacturing

Loading…

AbbVie | Oncology Similar Companies

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Loading…

NEWS

AbbVie | Oncology CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 14, 2026 08:00 AM

Cyber breach hit NZ’s largest medical oncology provider

Canopy Healthcare, an oncology and diagnostic imaging provider in New Zealand, experienced a cybersecurity incident in July, saying that an...

Read Article

November 03, 2025 08:00 AM

Beverly Hills Oncology Medical Group Data Breach Under Investigation

Shamis & Gentile, P.A. said impacted individuals who submit a claim may be eligible for compensation.

Read Article

October 31, 2025 07:00 AM

Beverly Hills Oncology Reports 5-Day Data Breach

Data breach at Beverly Hills Oncology exposed sensitive patient and staff info including SSNs and medical details.

Read Article

October 21, 2025 07:00 AM

Heywood Hospital Cybersecurity Incident Investigation

Strauss Borrelli PLLC, a leading data breach law firm, is investigating Heywood Hospital regarding its recent cybersecurity incident.

Read Article

October 05, 2025 07:00 AM

Cyberscammers are cashing in by exploiting cancer patients — we must stop them

Learn how cybercriminals are exploiting childhood cancer awareness to steal identities and scam donors. Protect yourself and others from...

Read Article

October 03, 2025 07:00 AM

October 2025 | Cancer & Cybersecurity Awareness Month - Security - South Africa

This October, we shine a light on two vital causes: 🎗️ Cancer Awareness, honouring the strength of patients, survivors, families,...

Read Article

September 10, 2025 01:26 PM

Ransomware attack hits Highlands Oncology, exposing over 113K patient info

Highlands Oncology Group has reported a significant data breach affecting more than 113000 individuals due to a ransomware attack.

Read Article

August 22, 2025 02:51 PM

Rachel James, AbbVie: Harnessing AI for corporate cybersecurity

Close-up of a laptop as AI News caught up with Rachel James, Principal. Share this story:.

Read Article

August 11, 2025 07:00 AM

Data breach at Dutch medical laboratory much larger than expected

Hackers steal data from 485000 women at a laboratory that conducts cervical cancer screening. Test results remain reliable.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-8718

SUMMARY

tls_opt_dtls_peer_connection_id_value_get() in subsys/net/lib/sockets/sockets_tls.c, which handles getsockopt(SOL_TLS, TLS_DTLS_PEER_CID_VALUE), passed the caller-supplied optval directly to mbedtls_ssl_get_peer_cid() without verifying the buffer was at least MBEDTLS_SSL_CID_OUT_LEN_MAX (default 32) bytes. mbedtls_ssl_get_peer_cid() copies the peer-negotiated DTLS Connection ID (length 1..MBEDTLS_SSL_CID_OUT_LEN_MAX) into that buffer without a destination-size parameter, so a caller-supplied optlen smaller than the CID causes a write of up to 31 bytes past the buffer end. In CONFIG_USERSPACE builds the getsockopt syscall verifier (z_vrfy_zsock_getsockopt) bounce-buffers the user's optval into a kernel allocation of exactly optlen bytes (k_usermode_alloc_from_copy -> z_thread_malloc), so an unprivileged user thread that passes a small optlen on a connected DTLS socket with Connection ID enabled induces a kernel-heap buffer overflow, with the overflowing content being the remote peer's CID. The defect requires CONFIG_MBEDTLS_SSL_DTLS_CONNECTION_ID, an established DTLS session with a negotiated peer CID, and (for the kernel-crossing case) CONFIG_USERSPACE. Introduced when the TLS_DTLS_CID option was added (v3.5.0). The fix rejects callers whose optlen is below MBEDTLS_SSL_CID_OUT_LEN_MAX with -EINVAL.

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: 8.4)

cvss3

Base Score: 8.4

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:C/C:N/I:H/A:H

Impact Score

5.8

Exploitability

REFERENCES

CVE-2026-48161

SUMMARY

react18-use is a React 19 use hook shim. Between 2026-05-19 01:07:01 and 2026-05-19 15:20:43, the default branch contained malicious commits 7b79148d1495a2505f9277da295a98cf176f4496 through 7b79148d1495a2505f9277da295a98cf176f4496 that executed remote attacker-controlled code on developer machines during `npm install`. The commits were removed by force-push, but local clones, forks, and direct-SHA URLs may still contain them, and `npm install` against an affected checkout will still execute the code today. The package was not published to npm. `src/install.js` was added and wired into the `postinstall` script. It fetched a JavaScript payload from an attacker-controlled HTTPS endpoint (configurable via an environment variable), disabled TLS verification, and evaluated the response as code with `require` available. Execution was deliberately skipped on CI and cloud/serverless environments, targeting developer workstations. The second-stage payload was attacker-hosted and cannot be reconstructed. Assume full compromise of anything reachable from a Node process with the user's permissions. Those who ran `npm install` against an affected checkout on a developer machine on or after 2026-05-19 01:07:01 should treat the machine as compromised, rotate every credential the machine could reach, audit account activity since 2026-05-19 01:07:01, and clean local clones.

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: )

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/dai-shi/react18-use/security/advisories/GHSA-32xh-vg5f-64fm

CVE-2026-11812

SUMMARY

The UpdateHub management subsystem (subsys/mgmt/updatehub/updatehub.c) drives every update operation through a single file-scope ctx structure that holds the CoAP block context, payload buffer, status code, socket, and a one-element poll-fd array fds[1]. Access to ctx was not serialized, and prepare_fds() wrote ctx.fds[ctx.nfds] and incremented ctx.nfds with no bounds check. Two independent paths mutate ctx concurrently: the background autohandler running on the system workqueue, and user-triggered operations reached through the updatehub run shell command, direct API calls, or — since the operations are exposed as syscalls — userspace threads. When a second flow enters prepare_fds() while ctx.nfds is already 1, the write lands one element past the array; by struct layout it overlaps the adjacent ctx.sock/ctx.nfds members. More broadly, the unsynchronized sharing lets two flows interleave connection setup and teardown, double-closing a socket descriptor or scribbling the shared buffers. The result is corruption of the update subsystem's internal state and denial of service of the firmware-update path; the out-of-bounds write is contained within the ctx structure and there is no demonstrated path to memory outside it or to code execution. Triggering requires a local actor able to invoke update operations (or, with CONFIG_USERSPACE, an unprivileged userspace thread) and to win a timing race against the background handler; remote peers cannot control the race timing. The fix serializes the entry points with a mutex and adds a bounds check to prepare_fds().

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: 2.5)

cvss3

Base Score: 2.5

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:L/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

REFERENCES

CVE-2026-11811

SUMMARY

The UpdateHub over-the-air update client's start_coap_client() in subsys/mgmt/updatehub/updatehub.c leaks the CoAP/DTLS socket descriptor on its connection-setup failure paths. The shared error: cleanup gated socket closing on a ret > 0 flag, but ret was set to -1 immediately after the socket was created, so when zsock_setsockopt() (DTLS) or zsock_connect() subsequently failed the gate was false and cleanup_connection() was never called. The open descriptor in the global ctx.sock was then overwritten by the next attempt, permanently leaking it from the socket / net_context pool until reboot. The failing setup path is reached every time the OTA client tries to contact the UpdateHub server and the connection cannot be established — driven automatically by the periodic autohandler() poll (and on demand via the updatehub_probe()/updatehub_update() API or the updatehub run shell command). The DTLS handshake/connect outcome is influenceable by a network or on-path attacker who drops, resets, or otherwise disrupts traffic to the server, and also fails naturally whenever the server is unreachable. Each failed attempt permanently leaks one descriptor; once the shared socket pool is exhausted, networking degrades device-wide until the device is rebooted, a denial-of-service condition. Severity is low because the leak rate is bounded by the configured OTA poll interval (default once per 24 hours), the effect is gradual and recovered by reboot, and only builds with the UpdateHub client enabled are affected. There is no memory-corruption, information-disclosure, or authentication impact.

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2025-30241

SUMMARY

Certain web interface components in affected TP-Link Aginet devices do not validate and sanitize user-supplied input properly before passing it to system-level command execution functions. An authenticated adjacent attacker may inject specially crafted input to execute arbitrary operation system commands with elevated privileges. Successful exploitation may allow execution of arbitrary system commands, potentially leading to full device compromise.

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: )

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:A/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://www.tp-link.com/us/support/faq/5239/

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…